CL2011002962A1 - Uso de al menos un ligando especifico de integrina para el tratamiento de cancer, y donde el medicamento es para ser usado en combinacion con al menos un agente adicional seleccionado de a) uno o mas agentes alquilantes y b) uno o mas agentes quimioterapeuticos diferente a los anteriores. - Google Patents

Uso de al menos un ligando especifico de integrina para el tratamiento de cancer, y donde el medicamento es para ser usado en combinacion con al menos un agente adicional seleccionado de a) uno o mas agentes alquilantes y b) uno o mas agentes quimioterapeuticos diferente a los anteriores.

Info

Publication number
CL2011002962A1
CL2011002962A1 CL2011002962A CL2011002962A CL2011002962A1 CL 2011002962 A1 CL2011002962 A1 CL 2011002962A1 CL 2011002962 A CL2011002962 A CL 2011002962A CL 2011002962 A CL2011002962 A CL 2011002962A CL 2011002962 A1 CL2011002962 A1 CL 2011002962A1
Authority
CL
Chile
Prior art keywords
cancer
drug
treatment
combination
agent selected
Prior art date
Application number
CL2011002962A
Other languages
English (en)
Inventor
Martin Andreas Picard
Ullrich Dotzauer Matthias Moyal Elizabeth Cohen Jonathan Bethe
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43223150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002962(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CL2011002962A1 publication Critical patent/CL2011002962A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Uso de al menos un ligando específico de integrina para el tratamiento de cáncer, y donde el medicamento es para ser usado en combinación con al menos un agente adicional seleccionado de A) Uno o más agentes alquilantes y B) Uno o más agentes quimioterapéuticos diferente a los anteriores.
CL2011002962A 2009-05-25 2011-11-24 Uso de al menos un ligando especifico de integrina para el tratamiento de cancer, y donde el medicamento es para ser usado en combinacion con al menos un agente adicional seleccionado de a) uno o mas agentes alquilantes y b) uno o mas agentes quimioterapeuticos diferente a los anteriores. CL2011002962A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09006941 2009-05-25

Publications (1)

Publication Number Publication Date
CL2011002962A1 true CL2011002962A1 (es) 2012-06-01

Family

ID=43223150

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002962A CL2011002962A1 (es) 2009-05-25 2011-11-24 Uso de al menos un ligando especifico de integrina para el tratamiento de cancer, y donde el medicamento es para ser usado en combinacion con al menos un agente adicional seleccionado de a) uno o mas agentes alquilantes y b) uno o mas agentes quimioterapeuticos diferente a los anteriores.

Country Status (16)

Country Link
US (1) US20120130146A1 (es)
EP (1) EP2445534A2 (es)
JP (1) JP2012528079A (es)
KR (1) KR20120104491A (es)
CN (1) CN102448497A (es)
AU (1) AU2010252280A1 (es)
BR (1) BRPI1011206A2 (es)
CA (1) CA2763275A1 (es)
CL (1) CL2011002962A1 (es)
EA (1) EA201101651A1 (es)
EC (1) ECSP11011552A (es)
IL (1) IL216537A0 (es)
MX (1) MX2011012491A (es)
NZ (1) NZ597339A (es)
SG (1) SG176103A1 (es)
WO (1) WO2010136168A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011278700A1 (en) * 2010-07-16 2013-02-28 Merck Patent Gmbh Peptide for use in the treatment of breast cancer and/or bone metastases
WO2013009701A2 (en) 2011-07-08 2013-01-17 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
WO2013072901A2 (en) 2011-11-17 2013-05-23 Btm Mazowsze Sp. Zo.O. Compositions and methods for treating glioma
KR101470700B1 (ko) * 2011-11-25 2014-12-12 서울대학교산학협력단 표적 항암제의 내성 극복 방법
SI3127544T1 (sl) * 2014-04-04 2021-12-31 Taiho Pharmaceutical Co., Ltd. Protitumorsko zdravilo, vsebujoče protitumorski kompleks platine in protitumorski ojačevalec učinka
US10806694B2 (en) 2014-10-14 2020-10-20 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
WO2016061256A1 (en) * 2014-10-14 2016-04-21 The University Of Chicago Nanoparticles for photodynamic therapy, x-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof
US11246877B2 (en) 2016-05-20 2022-02-15 The University Of Chicago Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof
WO2019002940A1 (en) * 2017-06-29 2019-01-03 Insightec, Ltd. TARGETED ADMINISTRATION AND DETERMINATION ENHANCED BY CAVITATION OF A MEDICAMENT
WO2019028250A1 (en) 2017-08-02 2019-02-07 The University Of Chicago NOMOGENEOUS ORGANOMETALLIC ORGANOMETRIC ORGANOMETRIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RODIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION THEREOF

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US5260291A (en) 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US4792525A (en) 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4517686A (en) 1982-08-04 1985-05-21 La Jolla Cancer Research Foundation Polypeptide
US4578079A (en) 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4589881A (en) 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
US4614517A (en) 1982-08-04 1986-09-30 La Jolla Cancer Research Foundation Tetrapeptide
US4661111A (en) 1982-08-04 1987-04-28 La Jolla Cancer Research Foundation Polypeptide
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
AU6290090A (en) 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
JP3583420B2 (ja) 1990-10-05 2004-11-04 メダレツクス・インコーポレーテツド 二特異的試薬を用いた標的免疫化
EP0563214A4 (en) 1990-12-04 1994-08-17 Wistar Inst Bifunctional antibodies and method of preparing same
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
US5407804A (en) 1992-05-22 1995-04-18 Applied Genetics Inc. Assays for O6 -methylguanine-DNA methyltransferase
GB9224888D0 (en) 1992-11-27 1993-01-13 Univ Singapore Monoclonal antibody
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
CA2190870A1 (en) 1994-05-27 1995-12-07 George D. Hartman Compounds for inhibiting osteoclast-mediated bone resorption
AU702661B2 (en) 1994-06-29 1999-02-25 Smithkline Beecham Corporation Vitronectin receptor antagonists
ZA955391B (en) 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
IT1271688B (it) 1994-08-04 1997-06-04 Menarini Ricerche Sud Spa Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche
WO1996006087A1 (en) 1994-08-22 1996-02-29 Smithkline Beecham Corporation Bicyclic compounds
WO1996026190A1 (en) 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
US5780426A (en) 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
ES2197950T3 (es) 1995-06-29 2004-01-16 Smithkline Beecham Corporation Antagonistas del receptor de la integrina.
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
KR19990076877A (ko) 1995-12-29 1999-10-25 스티븐 베네티아너 비트로넥틴 수용체 길항제
JP2000502354A (ja) 1995-12-29 2000-02-29 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体アンタゴニスト
CN1209060A (zh) 1995-12-29 1999-02-24 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂
DE69707843T2 (de) 1996-03-20 2002-05-16 Aventis Pharma S.A., Antony TRIZYCLISCHE VERBINDUNGEN MIT WIRKUNG AUF INTEGRINE, BESONDERS AUF DAS ALPHAvBETA3-INTEGRIN, VERFAHREN ZUR IHRER HERSTELLUNG UND ZWISCHENPRODUKTE DES VERFAHRENS, IHRE VERWENDUNG ALS ARZNEIMITTEL UND SIE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN
CA2251017A1 (en) 1996-04-10 1997-10-16 Mark E. Duggan .alpha.v.beta.3 antagonists
US5925655A (en) 1996-04-10 1999-07-20 Merck & Co., Inc. αv β3 antagonists
WO1997041844A1 (en) 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Combinations of angiostatic compounds
KR20000016301A (ko) 1996-05-31 2000-03-25 빙검 더글라스 에이. 혈관 형성 억제에 유용한 방법 및 조성물
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
WO1998008840A1 (en) 1996-08-29 1998-03-05 Merck & Co., Inc. Integrin antagonists
US5981546A (en) 1996-08-29 1999-11-09 Merck & Co., Inc. Integrin antagonists
EP0946180A4 (en) 1996-10-07 2003-07-23 Smithkline Beecham Corp METHODS FOR STIMULATING BONE FORMATION
ATE236626T1 (de) 1996-10-30 2003-04-15 Merck & Co Inc Integrin antagonist
EP0946164A4 (en) 1996-10-30 2000-08-23 Merck & Co Inc INTEGRIN ANTAGONISTS
US5919792A (en) 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
CA2272090A1 (en) 1996-12-09 1998-06-18 Matthew J. Fisher Integrin antagonists
DE19653646A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
DE19653647A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
DE19653645A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
CO4920232A1 (es) 1997-01-08 2000-05-29 Smithkline Beecham Corp Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin
AU729869B2 (en) 1997-01-17 2001-02-15 Merck & Co., Inc. Integrin antagonists
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
EP1000031A4 (en) 1997-07-25 2001-08-16 Smithkline Beecham Corp VITRONECTIN RECEPTOR ANTAGONISTS
AU8689798A (en) 1997-08-04 1999-02-22 Smithkline Beecham Corporation Integrin receptor antagonists
EP1027337A4 (en) 1997-09-04 2002-04-03 Smithkline Beecham Corp Integrin receptor Antagonist
PE122699A1 (es) 1997-09-19 2000-02-12 Smithkline Beecham Corp Antagonistas de receptores de vitronectina
FR2768734B1 (fr) 1997-09-24 2000-01-28 Roussel Uclaf Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
AU9577498A (en) 1997-09-24 1999-04-12 Smithkline Beecham Corporation Vitronectin receptor antagonist
WO1999015178A1 (en) 1997-09-24 1999-04-01 Smithkline Beecham Corporation Vitronectin receptor antagonist
FR2768736B1 (fr) 1997-09-24 2000-05-26 Roussel Uclaf Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
AU736026B2 (en) 1997-12-17 2001-07-26 Merck & Co., Inc. Integrin receptor antagonists
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
WO1999031061A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
ATE299023T1 (de) 1997-12-17 2005-07-15 Merck & Co Inc Integrinrezeptor antagonisten
IL136314A0 (en) 1997-12-17 2001-05-20 Merck & Co Inc Integrin receptor antagonists
DE69930723T2 (de) 1998-01-23 2006-11-16 Merck Patent Gmbh Verwendung des antikörpers 271.14d9.f8 (dsm acc2331) um die bindung zwischen alphavbeta6-integrin und fibronectin in vitro zu hemmen
AU747784B2 (en) 1998-07-29 2002-05-23 Merck & Co., Inc. Integrin receptor antagonists
JP2002522540A (ja) 1998-08-13 2002-07-23 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
CN1398189A (zh) 1998-12-23 2003-02-19 G.D.西尔公司 用于治疗肿瘤形成的放疗与cox－2抑制剂的联合治疗
DK1187592T3 (da) 1999-06-02 2007-11-05 Merck & Co Inc Alfa v-integrinreceptorantagonister
AU2001296511A1 (en) 2000-09-29 2002-04-08 The Johns Hopkins University School Of Medicine Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents
CN101370522A (zh) * 2006-01-18 2009-02-18 默克专利有限公司 使用整联蛋白配体治疗癌症的特别疗法
BRPI0806596A2 (pt) * 2007-01-18 2013-07-23 Merck Patent Ges Mit Berchraenkter Haftung medicamento e terapia especÍfica usando-se ligantes de integrina para o tratamento de cÂncer

Also Published As

Publication number Publication date
EP2445534A2 (en) 2012-05-02
IL216537A0 (en) 2012-02-29
SG176103A1 (en) 2011-12-29
KR20120104491A (ko) 2012-09-21
WO2010136168A3 (en) 2011-07-07
EA201101651A1 (ru) 2012-08-30
WO2010136168A8 (en) 2011-09-22
ECSP11011552A (es) 2012-01-31
WO2010136168A2 (en) 2010-12-02
US20120130146A1 (en) 2012-05-24
NZ597339A (en) 2013-10-25
BRPI1011206A2 (pt) 2016-03-15
CN102448497A (zh) 2012-05-09
CA2763275A1 (en) 2010-12-02
AU2010252280A1 (en) 2012-01-19
JP2012528079A (ja) 2012-11-12
MX2011012491A (es) 2011-12-14

Similar Documents

Publication Publication Date Title
CL2012000772A1 (es) Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
CL2009000545A1 (es) Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
CL2011001811A1 (es) Un metodo para tratar un paciente que ha sufrido un infarto agudo al miocardio que comprende el uso de un agente antifibrotico.
CO6341551A2 (es) Agentes quimioterapeuticos de cannabinoides en combinacion con no cannabinoides (e.g) agentes serm o de alquilaciion)
UY33984A (es) Uso de 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
BR112015016681A8 (pt) uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático
CL2007000876A1 (es) Uso de un antagonista del factor de crecimiento endotelial vascular (vegf) en combinacion con un segundo agente que comprende un agente reductor de celula mieloide para tratar un tumor resistente en un sujeto; y metodo de diagnostico del tumor.
CL2008001076A1 (es) Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2007002994A1 (es) Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
ECSP10010559A (es) Compuestos heterociclicos novedosos y usos de los mismos
CL2015001207A1 (es) Composición para prevenir o tratar diabetes, diabesidad o complicaciones diabéticas, que comprende un análogo de oxintomodulina; y uso de la composición.
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2012001422A1 (es) Compuestos derivados de sulfonil benzamidas sustituidas, inductores de apoptosis con selectividad por bcl-2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2013000718A1 (es) Un complejo de inclusion que comprende a) una ciclodextrina, b) fulvestrant y c) un portador; su metodo de preparacion; formulacion y forma de dosificacion que comprende al complejo; preparacion que comprende al complejo o a la formulación; y su uso en el tratamiento del cancer y lupus eritematoso sistemico, entre otras enfermedades.
CL2013001009A1 (es) Compuestos heterociclicos fusionados; composicion farmaceutica que los comprende, y uso en el tratamiento de un trastorno proliferativo tal como cancer.
CL2015003595A1 (es) Inhibidores/antiandrógenos novedosos de cyp17
CL2013000881A1 (es) Combinaciones farmacéuticas que comprenden un componente (a) que corresponden a compuestos derivados de difenilurea omega-carboxiaril-sustituidos, (b) compuestos derivados de n-(2-arilamino)arilsulfonamida y (c) que son uno o más agentes farmaceuticos adicionales; y su uso en el tratamiento del cancer
PH12018500391A1 (en) Single-use multi-layered ticket and redeeming technique